GlassScriptPhysician profile
Douglas B Colman
NPI 1851368625
$1,986.43
in general payments reported to CMS, 2019-2025
29 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $19.09 · 2021: $91.28 · 2022: $444 · 2023: $433 · 2024: $380 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.42 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $201.97 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $166.40 | 2021-2025 | Ubrelvy |
| Amgen INC. | $133.29 | 2019-2024 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $128.59 | 2023-2025 | Mounjaro |
| Stryker Corporation | $121.02 | 2025 | Blueprint Patient Specific Instrumentation |
| Glaxosmithkline, LLC. | $111.92 | 2019-2024 | Shingrix |
| Amarin Pharma, INC. | $110.79 | 2019-2022 | |
| Almatica Pharma LLC | $96.44 | 2021-2022 | |
| Boston Scientific Corporation | $71.78 | 2022-2024 | |
| Pfizer INC. | $66.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $53.39 | 2020-2022 | |
| Astellas Pharma US INC | $43.29 | 2019-2024 | Veozah |
| Smith+Nephew, INC. | $39.66 | 2024 | Real Intelligence, Or3o Dual Mobility |
| Biosense Webster, INC. | $33.77 | 2023 | Carto 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $33.09 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $31.60 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $30.24 | 2022-2025 | Keveyis |
| Daiichi Sankyo INC. | $25.80 | 2022 | |
| Abiomed | $22.10 | 2023 | Impella |
| Medtronic, INC. | $18.23 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.15 | 2019 | |
| Sanofi Pasteur INC. | $16.92 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.91 | 2019 | |
| Lucid Diagnostics INC. | $14.55 | 2023 | |
| Merck Sharp & Dohme LLC | $13.88 | 2022 | |
| Medicure Pharma INC. | $13.49 | 2025 | Zypitamag |
| Allergan, INC. | $13.13 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Colman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.